One of the most fatal cancers, making it the seventh-highest rate of cancer-related death globally is pancreatic cancer. Most individuals with pancreatic cancer are asymptomatic until the disease has progressed to an advanced stage where surgery cannot be a potentially curative intervention. The modality of treatment (especially surgery) is usually chosen based on the stage and resectability of the tumor. Provide a proper review of the effect of surgery in the resectable pancreatic cancer treatment. For articles selection the PubMed database was used, and the following keys were utilized in the mesh ((“pancreatic cancer"[Mesh]) AND (“resectable” [Mesh]) OR (“surgery"[Mesh])). To improve the rate of curative resection, patients with borderline resectable cancers can benefit from chemoradiation or preoperative (neoadjuvant) chemotherapy alone. Moreover, even in patients with resectable tumors, neoadjuvant chemotherapy has been recommended to ensure that systemic treatment is completed. Nevertheless, the only current potentially curative treatment option is surgical excision with an aggressive purpose. Depending on the location and type of tumor, a pancreatoduodenectomy, distal pancreatectomy, or complete pancreatectomy is done routinely.